CLINICAL SIGNIFICANCE OF INCREASED SERUM NEOPTERIN IN CHRONIC KIDNEY FAILURE AS A BIOMarker OF CELL-MEDIATED IMMUNITY

KLINIČKI ZNAČAJ POVEĆANOG SERUMSKOG NEOPTERINA U HRONIČNOM OŠTEĆENJU BUBREGA KAO BIOMARKER ČELIJSKI POSREDOVANOG IMUNITETA

Songül Ünüvar1, Hamza Aslanhan2

1Department of Pharmaceutical Toxicology, Faculty of Pharmacy, İnönü University, Malatya, Turkey
2Department of Family Medicine, Faculty of Medicine, Dicle University, Diyarbakır, Turkey

Summary

Background: Neopterin is a pyrazino-pyrimidine compound which is used as a marker of cell-mediated immunity in a variety of diseases. It is known that neopterin levels increase in diseases where interferon-gamma (IFN-γ) stimulation is present, and also as a result of deficiencies in renal function, given that the primary means of elimination of neopterin is through the kidneys. In this study, we aimed to investigate the role of increased neopterin levels as a prognostic biomarker in patients with impaired renal function.

Methods: A total of 90 individuals including 63 patients with chronic kidney failure (CKF) and 27 healthy volunteers were included in the study. Serum neopterin concentrations were measured using the enzyme-linked immunosorbent assay. A Mann-Whitney U test and a Pearson Correlation Test were used in the statistical analysis, with a p value of <0.05 being considered statistically significant.

Results: The mean age was 52.21±0.16 years in the patient group and 56.55±0.32 years in the control group. In the CKF patients, serum neopterin levels increased to a significantly greater degree than in the control group (p<0.001), while no statistically significant correlation was identified between serum neopterin levels and age (p>0.05). conclusions: A significant increase was found in the serum neopterin levels in the CKF patients, due to both the triggering of the disease and the reduction of neopterin elimination.

Keywords: cell-mediated immunity, chronic kidney failure, neopterin, renal diseases

Address for correspondence:
Songül Ünüvar
Department of Pharmaceutical Toxicology, Faculty of Pharmacy, İnönü University, Malatya, Turkey
Tel: +90 422 341 0660; Fax: +90 422 341 1217
e-mail: songul.unuvar@inonu.edu.tr
Introduction

Neopterin is a pyrazino-pyrimidine compound that is synthesized by monocytes and macrophages as a result of stimulation with endotoxin and IFN-γ by activated T cells. Neopterin levels in body fluids are elevated in a variety of diseases where T cells or macrophages are activated (1–4), and has been identified as a marker of disease in a variety of conditions, such as viral infections, inflammatory diseases, autoimmune diseases, neurodegenerative diseases and some types of cancer (1, 5). Accordingly, neopterin levels are used in evaluations of disease activity and prognosis in various pathologies (5–7).

In a previous study, increased urinary neopterin levels were reported to be associated with an increase in serum creatinine levels in nephrotic syndrome, chronic renal failure, and end-stage renal disease (6). Although it is suggested in the aforementioned study that neopterin is not specific in the evaluation of disease prognosis, there are many studies suggesting that neopterin is useful as a biological marker when following-up the clinical course of the disease or assess prognosis. Several studies have reported that serum or urine neopterin levels increase in cases of idiopathic or primary nephrotic syndrome, chronic and acute glomerulonephritis, and different stages of chronic kidney disease (7–10), and it has been also shown that neopterin levels are elevated in patients with end-stage renal disease (ESRD) undergoing long-term hemodialysis, and that this increase is correlated with the duration of hemodialysis. Also in the aforementioned study it is demonstrated that in cases of human immunodeficiency virus (HIV) infection, the risk of developing acquired immune deficiency syndrome (AIDS) may increase in patients undergoing dialysis for more than one year. This increase has been also associated with various interactions between blood coagulation molecules and hemodialysis membranes and activated cellular immune response as a result of exposure to the dialysis membrane (11).

Chronic kidney disease is defined as the progressive loss of renal function over a period of months or years. There are no specific signs of impairment in renal function although the presence of diabetes and/or high blood pressure greatly increases the chance of kidney disease (12).

In the present study we investigate whether serum neopterin levels increase more in patients with CKF than in healthy individuals, and evaluate the correlation between serum neopterin levels and age.

Materials and Methods

Participants

A total of 90 individuals including 63 CKF patients and 27 healthy volunteers were included in the study. The health status of all individuals in the control group was inquired in detail, and those with no health problems were included in the control group. The study group consisted of patients undergoing dialysis treatment and diagnosed with CKF. The study was approved by the local Ethics Committee of Inonu University, Faculty of Medicine and was carried out in accordance with the principles of the Declaration of Helsinki.

Blood sampling

Serum neopterin levels were measured using the following method: Blood samples were taken prior to dialysis in CKF patients. Serum was obtained from coagulated blood samples and collected in a shaded tube, as neopterin is sensitive to light. The blood samples were separated to sera by centrifugation at 4 °C for 10 min at 3,000 rpm and the samples were stored at -20 °C until analysis.

Neopterin measurement

Neopterin was measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits (DRG Diagnostics GmbH, Marburg, Germany). Optical density was measured at 450 nm, with serum neopterin levels expressed in nmol/L.

Statistical analysis

The statistical analysis was carried out using SPSS version 11.5 software (SPSS Inc., Chicago, IL, USA), with continuous variables expressed in mean± standard error (SEM). A Mann-Whitney U test was used to compare the patient and control groups. The relationship between serum neopterin levels and age was determined using a Pearson Correlation Test and the Linear Regression method, and a p value <0.05 was considered statistically significant.

Results

The mean age was 52.21±0.16 (range: 32 to 71) years and 56.55±0.32 (range: 43 to 69) years in the patient and control groups, respectively. Serum neopterin levels were higher in the CKF patients (34.22±0.50 nmol/L) than in the control group (8.19±0.08 nmol/L) (Figure 1), to a statistically significant degree (p<0.001), as a result of the disease itself and the decreased disease-related elimination.

As shown in Figure 2, although a positive correlation (r=0.253) was identified between serum neopterin levels and age in the control group, this age-related increase was not statistically significant (p=0.203).

The age-related changes in serum neopterin concentrations in CKF patients are presented in
Similar to the control group, an increase was noted in serum neopterin levels (r=0.043) with increasing age in the patient group although this positive correlation between the age and neopterin was not statistically significant (p=0.738).

Discussion

Neopterin is a biochemical marker of cellular immune response and is a member of a group of compounds known as pteridines (13), which are pyrazino-(2,3-d) pyrimidine derivative compounds synthesized by guanosine triphosphate (GTP). At 253 daltons neopterin is approximately twice the size of creatinine (113 daltons). Urinary neopterin levels were first observed to increase in viral infections and tumors in 1979 (14). In the 1980s, neopterin levels were a popular predictor of postoperative acute rejection reactions and viral infections in transplantation studies, but have since been «forgotten» as a biomarker (15). A significant abnormality has been found in the pteridine metabolism in patients with CKF in subsequent studies (10).

Neopterin is produced by monocyte, macrophage and monocyte-derived dendritic cells as a result of IFN-γ or endotoxin stimulation (1, 5, 16). Activated Th 1 lymphocytes secrete IFN-γ during cellular immune response. Activation of Th 1 lymphocytes is the main stimulus for neopterin production and secretion (3, 17). The secreted IFN-γ binds rapidly to the target structures or is neutralized with soluble receptors, although neopterin is biochemically inert and its serum concentrations are closely related to the activity of the cellular immune system (2).

Recent studies have suggested that elevated serum and urine neopterin levels may be used as diagnostic or prognostic markers in a variety of conditions, including neuropsychiatric disorders (18), renal allograft rejection (19), hepatitis and, HIV, in such viral infections as cytomegalovirus, in bacterial infections (1, 20–22), in silicosis patients (23), in such autoimmune diseases as active juvenile idiopathic arthritis (24), in tumors of, for example, the breast carcinoma, colorectal cancer (25, 26), in type-1 and type-2 diabetes patients with diabetic foot syndrome (27) and in coronary and peripheral artery disease, atrial fibrillation (4), left ventricular dysfunction, heart failure (15).

Circulating cytokines and other markers of inflammation are significantly elevated in patients with CKF. In previous studies, neopterin levels have been found to be higher in patients with a lower glomerular filtration rate, which suggests that renal elimination is impaired, that uremia increases or that inflammation has an adverse effect on renal function in such cases (28).

Chronic systemic inflammation is a result of the release of pro-inflammatory molecules (cytokines) from immune-related cells and the chronic activation of the innate immune system. The C-reactive protein (CRP) is a marker of systemic inflammation (29), with a relationship being established with renal functions in the early stages of CKF (30). Serum neopterin levels have been found to be high in patients with CKF.
before dialysis, and it has been reported that a correlation exists between inflammation markers and neopterin, including IL-6, hsCRP, TNF-α, IFN-γ and hyaluronan (9, 28). It has been suggested that neopterin, as a marker of activation of the cellular immune response due to IFN-γ release, can better reflect uremia-related changes in the immune system seen in cases of renal transplantation than inflammatory markers (16).

Concentrations of neopterin increase due to impaired renal neopterin clearance and/or increased production due to systemic inflammation (9), and neopterin levels are also an indicator of oxidative stress, including the production of reactive oxygen species (ROS), in addition to reflecting the degree of cellular immune activation (3, 16, 17). Neopterin plays an effector role in enhancing the effects of reactive oxygen species, and displays pro-oxidant properties (3, 17). Since neopterin is chemically inert, and elimination occurs only through the kidneys, serum neopterin levels are elevated in diseases in which inflammatory activity does not increase, but renal function decreases (31).

Chronic kidney disease is a global health problem, and health expenditures for this group of patients is 1.8 times higher than for patients without chronic kidney disease. The mean cost of a dialysis patient is 10.3 times greater than of a patient without chronic kidney disease (32). Incidences of ESRD increased from 86.8 million to 347 million within a year, and it was reported that the rate increased steadily until 2002, but has since remained stable (33).

Several studies have been conducted to investigate this biomarker in cases of impaired renal function, and it has been suggested that neopterin levels may also be used in dose adjustment in clinical practice. Accordingly, in addition to the recognition of neopterin as a biological marker, this property should not be overlooked. Some authors have suggested the use of neopterin as a possible marker in evaluating the efficacy of immunosuppressive therapy. There is currently no drug on the market that specifically reduces neopterin levels, although an overall increase in the level of immunosuppression is associated with low serum neopterin levels. In addition, it is still unknown whether a therapeutic strategy that enhances the elimination of neopterin or inhibits neopterin production and release would be efficacious in clinical practice.

In conclusion, the results of our study suggest that serum neopterin may be a useful marker in predicting disease activity and prognosis in patients with CKF although these results should be supported with further prospective long-term studies of a larger group of patients.

Acknowledgments. None.

Conflict of interest statement

The authors stated that they have no conflicts of interest regarding the publication of this article.

References

1. Eisenhut M. Neopterin in diagnosis and monitoring of infectious diseases. J Biomark 2013; 196432: 2013.
2. Pihlstrøm H, Mjøen G, März W, Olav Dahlê D, Abedini S, Holme I, et al. Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients. Clin Transplant 2014; 28(1): 111–9.
3. Gostner JM, Becker K, Fuchs D, Sucher R. Redox regulation of the immune response. Redox Rep 2013; 18(3): 88–94.
4. Zuo H, Nygard O, Ueland PM, Vollset SE, Svingen GFT, Pedersen ER, et al. Association of plasma neopterin with risk of an inpatient hospital diagnosis of atrial fibrillation: results from two prospective cohort studies. J Intern Med 2018; doi: 10.1111/joim.12748.
5. Hoffmann G, Wirléitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003; 52(8): 315-21.
6. Lhee HY, Kim H, Joo KJ, Jung SS, Lee KB. The clinical significance of serum and urinary neopterin levels in several renal diseases. J Korean Med Sci 2006; 21(4): 678–82.
7. Bakr A, Rageh I, el-Azouny M, Deyab S, Lotfy H. Serum neopterin levels in children with primary nephrotic syndrome. Acta Paediatr 2006; 95(7): 854–6.
8. Formanowicz D. Neopterin in patients with chronic kidney disease and patients with coronary artery disease. Biotechnologia 2012; 93(1): 59–67.
9. Yadav AK, Sharma V, Jha V. Association between serum neopterin and inflammatory activation in chronic kidney disease. Mediators Inflamm 2012; 476979: 2012.
10. Ristovski-Kornic D, Stefanović A, Kotur-Stevuljević J, Željković A, Spasojević-Kalimanovska V, Vekić J, Miljković M, Paripović D, Peco-Antić A, Jelić-Ivanović Z. Association of Myeloperoxidase and the Atherogenic Index of Plasma in Children with End-Stage Renal Disease. J Med Biochem 2017; 36: 23–31.
11. Fuchs D, Hausen A, Reibnegger G, Werner ER, von Dittrich PV, Wachter H. Neopterin levels in long-term hemodialysis. Clin Nephrol 1988; 30(4): 220–4.
12. Panjeta M, Tahirović I, Sofić E, Ćorić J, Dervišević A. Interpretation of erythropoietin and haemoglobin levels in patients with various stages of chronic kidney disease. J Med Biochem 2017; 36: 145–52.

13. Pingle SK, Tumane RG, Jawade AA. Neopterin: Biomarker of cell-mediated immunity and potent usage as biomarker in silicosis and other occupational diseases. Indian J Occup Environ Med 2008; 12(3): 107–111.

14. Wachter H, Hausen A, Grassmayr K. Increased urinary excretion of neopterin in patients with malignant tumors and with virus diseases. Hoppe-Seyler's Z Physiol Chem 1979; 360: 1957–60.

15. De Rosa S, Cirillo P, Pacileo M, Petrillo G, D'Ascoli GL, Maresca F, et al. Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharmacol 2011; 9(2): 188–99.

16. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3(2): 175–87.

17. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, et al. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993; 321(1): 89–92.

18. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Serum neopterin as an indicator of increased risk of renal allograft rejection. Transpl Immunol 2013; 28(2-3): 81–5.

19. Uysal HK, Sohrabi P, Habip Z, Saribas S, Kocazeybek E, Seyhan F, et al. Neopterin and soluble CD14 levels as indicators of immune activation in cases with indeterminate pattern and true positive HIV-1 infection. PLoS ONE 2016; 11(3): e0152258.

20. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322(3): 1666–72.

21. Halota W, Jaruga B, Pawłowska M. Serum neopterin and beta2-microglobulin concentration as prognostic markers of AIDS. Pol Merkur Lek 2002; 13(74): 126–8.

22. Prakova G, Gidikova P, Slavov E, Sandeva G, Stanilova S. The Potential role of neopterin as a biomarker for silicosis. Trakia J Sci 2005; 5(4): 37–41.

23. Abu Shady MM, Fathy HA, Ali A, Youness ER, Fathy GA. Association of neopterin as a marker of immune system activation and juvenile rheumatoid arthritis activity. J Pediatr (Rio J) 2015; 91: 352–7.

24. Kalaábová H, Krkicová L, Kasparová M, Plísek J, Loco J, Hyspler R, et al. Prognostic significance of increased urinary neopterin concentrations in patients with breast carcinoma. Eur J Gynaecol Oncol 2011; 32(5): 525–9.

25. Melichar B, Solichová D, Melicharová K, Malárová E, Cermanová M, Zádák Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006; 21(3): 190–8.

26. Al-Nimer MS, Dezayee ZMI. Assessment of serum neopterin as an inflammatory and cardiovascular marker in type 1 and 2 diabetes complicated by diabetic foot syndrome: a comparative study. Clin Diabetol 2018; 7(2): 91–6.

27. Melichar B, Solichová D, Melicharová K, Malárová E, Cermanová M, Zádák Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006; 21(3): 190–8.

28. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63(2): 654–61.

29. Musiał K, Bargenda A, Drożd D, Zwolińska D. New markers of inflammation and tubular damage in children with chronic kidney disease. Dis Markers 2017; 2017: 9389432.

30. Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol 2004; 15(5): 1363–4.

31. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al. US Renal Data System 2012 Annual Data Report. Am J Kidney Dis 2013; 61(Suppl 1): A7, e1-476.